Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results›References

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results · References

References

CC BY 4.0 · NIHR Journals Library · approximately 6 min read

  1. WingK, WilliamsonE, CarpenterJR, WiseL, SchneeweissS, SmeethL, et al.Real-world effects of medications for chronic obstructive pulmonary disease: protocol for a UK population-based non-interventional cohort study with validation against randomised trial results. BMJ Open2018;8:e019475. 10.1136/bmjopen-2017-019475
  2. The Healthcare Commission. Clearing the Air: A National Study Of Chronic Pulmonary Disease. London: The Healthcare Commission; 2006.
  3. CalverleyPM, AndersonJA, CelliB, FergusonGT, JenkinsC, JonesPW, et al.Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med2007;356:775–89. 10.1056/NEJMoa06307017314337
  4. TashkinDP, CelliB, SennS, BurkhartD, KestenS, MenjogeS, DecramerM, UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med2008;359:1543–54. 10.1056/NEJMoa080580018836213
  5. National Institute for Health and Care Excellence. Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management. 2010. URL: www.nice.org.uk/guidance/cg101 (accessed 26 May 2017).
  6. FergusonGT, AnzuetoA, FeiR, EmmettA, KnobilK, KalbergC, et al.Maintenance pharmacotherapy of mild and moderate COPD: what is the evidence?Respir Med2011;105:1268–74. 10.1016/j.rmed.2011.02.00521353516
  7. European Union. Regulation (EU) No 1235/2010 of the European Parliament and of the Council. 2010. URL: http://ec.europa.eu/health//sites/health/files/files/eudralex/vol-1/reg_2010_1235/reg_2010_1235_en.pdf (accessed 2 Jaune 2021).
  8. SpringS. Guidance for Industry Postmarketing Studies and Clinical Trials – Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act. URL: www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm (accessed 13 June 2017).
  9. HerrettE, GallagherAM, BhaskaranK, ForbesH, MathurR, van StaaT, SmeethL. Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol2015;44:827–36. 10.1093/ije/dyv09826050254
  10. HerrettE, ThomasSL, SchoonenWM, SmeethL, HallAJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol2010;69:4–14. 10.1111/j.1365-2125.2009.03537.x20078607
  11. QuintJK, MüllerovaH, DiSantostefanoRL, ForbesH, EatonS, HurstJR, et al.Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). BMJ Open2014;4:e005540. 10.1136/bmjopen-2014-005540
  12. MillettER, QuintJK, SmeethL, DanielRM, ThomasSL. Incidence of community-acquired lower respiratory tract infections and pneumonia among older adults in the United Kingdom: a population-based study. PLOS ONE2013;8:e75131. 10.1371/journal.pone.007513124040394
  13. RothnieKJ, MüllerováH, HurstJR, SmeethL, DavisK, ThomasSL, QuintJK. Validation of the recording of acute exacerbations of COPD in UK primary care electronic healthcare records. PLOS ONE2016;11:e0151357. 10.1371/journal.pone.015135726959820
  14. NissenF, MoralesDR, MullerovaH, SmeethL, DouglasIJ, QuintJK. Validation of asthma recording in the Clinical Practice Research Datalink (CPRD). BMJ Open2017;7:e017474. 10.1136/bmjopen-2017-017474
  15. WingK, WilliamsonE, CarpenterJR, WiseL, SchneeweissS, SmeethL, et al.Real world effects of COPD medications: a cohort study with validation against RCT results. Eur Respir J2021;57:2001586. 10.1183/13993003.01586-202033093119
  16. DouglasI, EvansS, SmeethL. Effect of statin treatment on short term mortality after pneumonia episode: cohort study. BMJ2011;342:d1642. 10.1136/bmj.d164221471172
  17. WilliamsonE, MorleyR, LucasA, CarpenterJ. Propensity scores: from naive enthusiasm to intuitive understanding. Stat Methods Med Res2012;21:273–93. 10.1177/096228021039448321262780
  18. WilliamsonEJ, ForbesA. Introduction to propensity scores. Respirology2014;19:625–35. 10.1111/resp.1231224889820
  19. RootAA, WongAY, Ghebremichael-WeldeselassieY, SmeethL, BhaskaranK, EvansSJ, et al.Evaluation of the risk of cardiovascular events with clarithromycin using both propensity score and self-controlled study designs. Br J Clin Pharmacol2016;82:512–21. 10.1111/bcp.1298327090996
  20. National Institute for Health and Care Excellence. Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management. URL: www.nice.org.uk/guidance/ng115 (accessed 3 June 2019).
  21. ConcatoJ, ShahN, HorwitzRI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med2000;342:1887–92. 10.1056/NEJM20000622342250710861325
  22. GolderS, LokeYK, BlandM. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLOS Med2011;8:e1001026. 10.1371/journal.pmed.100102621559325
  23. DeeksJJ, DinnesJ, D’AmicoR, SowdenAJ, SakarovitchC, SongF, et al.Evaluating non-randomised intervention studies. Health Technol Assess2003;7(27). 10.3310/hta7270
  24. LawlorDA, Davey SmithG, KunduD, BruckdorferKR, EbrahimS. Those confounded vitamins: what can we learn from the differences between observational versus randomised trial evidence?Lancet2004;363:1724–7. 10.1016/S0140-6736(04)16260-015158637
  25. VandenbrouckeJP. The HRT controversy: observational studies and RCTs fall in line. Lancet2009;373:1233–5. 10.1016/S0140-6736(09)60708-X19362661
  26. DanaeiG, RodríguezLA, CanteroOF, LoganR, HernánMA. Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease. Stat Methods Med Res2013;22:70–96. 10.1177/096228021140360322016461
  27. DouglasIJ, EvansSJ, PocockS, SmeethL. The risk of fractures associated with thiazolidinediones: a self-controlled case-series study. PLOS Med2009;6:e1000154. 10.1371/journal.pmed.100015419787025
  28. LanganSM, SmeethL, MargolisDJ, ThomasSL. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLOS Med2013;10:e1001420. 10.1371/journal.pmed.100142023585738
  29. SchneeweissS, SeegerJD, LandonJ, WalkerAM. Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med2008;358:771–83. 10.1056/NEJMoa070757118287600
  30. HernánMA, AlonsoA, LoganR, GrodsteinF, MichelsKB, WillettWC, et al.Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology2008;19:766–79. 10.1097/EDE.0b013e3181875e6118854702
  31. RossouwJE, AndersonGL, PrenticeRL, LaCroixAZ, KooperbergC, StefanickML, et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA2002;288:321–33. 10.1001/jama.288.3.32112117397
  32. SmeethL, DouglasI, HallAJ, HubbardR, EvansS. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol2009;67:99–109. 10.1111/j.1365-2125.2008.03308.x19006546
  33. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet2002;360:7–22. 10.1016/S0140-6736(02)09327-312114036
  34. FralickM, KesselheimAS, AvornJ, SchneeweissS. Use of health care databases to support supplemental indications of approved medications. JAMA Intern Med2018;178:55–63. 10.1001/jamainternmed.2017.391929159410
  35. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med2008;358:1547–59. 10.1056/NEJMoa080131718378520
  36. NanniniLJ, LassersonTJ, PooleP. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev2012;9:CD006829. 10.1002/14651858.CD006829.pub2
  37. SorianoJB, VestboJ, PrideNB, KiriV, MadenC, MaierWC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J2002;20:819–25. 10.1183/09031936.02.0030130212412670
  38. MapelDW, HurleyJS, RoblinD, RobertsM, DavisKJ, SchreinerR, FrostFJ. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists. Respir Med2006;100:595–609. 10.1016/j.rmed.2005.08.00616199151
  39. SuissaS. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J2004;23:391–5. 10.1183/09031936.04.0006250415065827
  40. SuissaS, PatenaudeV, LapiF, ErnstP. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax2013;68:1029–36. 10.1136/thoraxjnl-2012-20287224130228
  41. ErnstP, GonzalezAV, BrassardP, SuissaS. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med2007;176:162–6. 10.1164/rccm.200611-1630OC17400730
  42. SuissaS, Dell’AnielloS, ErnstP. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study. Lancet Respir Med2018;6:855–62. 10.1016/S2213-2600(18)30368-030343028
  43. BogartM, StanfordRH, LalibertéF, GermainG, WuJW, DuhMS. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis2019;14:343–52. 10.2147/COPD.S18465330863037
  44. MuellerS, WilkeT, BechtelB, PunekarYS, MitznerK, VirchowJC. Non-persistence and non-adherence to long-acting COPD medication therapy: a retrospective cohort study based on a large German claims dataset. Respir Med2017;122:1–11. 10.1016/j.rmed.2016.11.00827993284
  45. KyriacouDN, LewisRJ. Confounding by indication in clinical research. JAMA2016;316:1818–19. 10.1001/jama.2016.1643527802529
  46. YoshidaK, SolomonDH, KimSC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol2015;11:437–41. 10.1038/nrrheum.2015.3025800216
  47. GagneJJ, FiremanB, RyanPB, MaclureM, GerhardT, TohS, et al.Design considerations in an active medical product safety monitoring system. Pharmacoepidemiol Drug Saf2012;21:32–40. 10.1002/pds.231622262591
  48. NørgaardM, EhrensteinV, VandenbrouckeJP. Confounding in observational studies based on large health care databases: problems and potential solutions – a primer for the clinician. Clin Epidemiol2017;9:185–93. 10.2147/CLEP.S12987928405173
  49. RCT DUPLICATE – Home. URL: https://aetion.com/company/news/first-rct-duplicate-findings-published-in-circulation/ (accessed 15 October 2021).
  50. FriedTR, Vaz FragosoCA, RabowMW. Caring for the older person with chronic obstructive pulmonary disease. JAMA2012;308:1254–63. 10.1001/jama.2012.1242223011715
  51. FergusonGT, BuhlR, BothnerU, HozA, VoßF, AnzuetoA, CalverleyPMA. Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. Respir Med2018;143:67–73. 10.1016/j.rmed.2018.08.01230261995
  52. RayR, TombsL, NayaI, ComptonC, LipsonDA, BoucotI. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: a pooled post hoc analysis of seven clinical trials. Pulm Pharmacol Ther2019;57:101802. 10.1016/j.pupt.2019.10180231096036
  53. LeeH, RyuJ, ChungSJ, ParkDW, SohnJW, YoonHJ, KimSH. Coexisting COPD increases mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study. Allergy Asthma Immunol Res2020;12:821–31. 10.4168/aair.2020.12.5.82132638562
  54. HaradaT, YamasakiA, FukushimaT, HashimotoK, TakataM, KodaniM, et al.Causes of death in patients with asthma and asthma-chronic obstructive pulmonary disease overlap syndrome. Int J Chron Obstruct Pulmon Dis2015;10:595–602. 10.2147/COPD.S7749125834418
  55. SinghD, D’UrzoAD, DonohueJF, KerwinEM. Weighing the evidence for pharmacological treatment interventions in mild COPD; a narrative perspective. Respir Res2019;20:141. 10.1186/s12931-019-1108-931286970
  56. GartlehnerG, HansenRA, CarsonSS, LohrKN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med2006;4:253–62. 10.1370/afm.51716735528
  57. JonesPW, WillitsLR, BurgePS, CalverleyPM, Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J2003;21:68–73. 10.1183/09031936.03.0001330312570111
  58. WolfA, DedmanD, CampbellJ, BoothH, LunnD, ChapmanJ, MylesP. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol2019;48:1740–1740g. 10.1093/ije/dyz03430859197
← Overall conclusionsAcknowledgements →

Attribution. Kevin Wing; Elizabeth Williamson; James R Carpenter; Lesley Wise; Sebastian Schneeweiss; Liam Smeeth et al. (2021). Medications for chronic obstructive pulmonary disease: a historical non-interventional cohort study with validation against RCT results. NIHR Journals Library. Copyright © 2021 Wing et al. This work was produced by Wing et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited. Licensed under CC BY 4.0. NCBI Bookshelf NBK573211. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support